RED:As per NHSE commissioning intentions. For the treatment of adults with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent,
a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. (Decision date - January 2024)
